Post by Astrin Biosciences

For nearly half of women who have dense breast tissue, mammograms are unreliable. This creates a clinical gap and a financial burden. As Astrin’s Scientific Advisor, Barbara Levy, MD, FACOG, FACS explains, “At best, it can tell you that something exists in the breast, not what it is.” In this article for Contemporary OB/GYN, Dr. Levy gives us hope for accessibility and effectiveness in early breast cancer detection. She calls for federal reform to require coverage for follow-up, transparency on additional costs, and insurance policy changes to reflect the new evidence. At Astrin, we are working to provide a solution that checks off these boxes, and does not force women to sacrifice their healthcare due to financial constraints. That’s why we created the Certitude Test—the first non-imaging blood test for breast cancer—for patients and providers. Read more of Dr. Levy’s perspective here —> https://lnkd.in/eFsqQyU2 #BreastCancerScreening #WomensHealth #CancerBloodTest